Enterprise Value
-1.388M
Cash
4.799M
Avg Qtr Burn
-772K
Short % of Float
6.81%
Insider Ownership
35.63%
Institutional Own.
8.59%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ADAIR (proprietary abuse-deterrent formulation of immediate-release) Details Attention deficit hyperactivity disorder | Phase 3 Update | |
GRI-0621 Details Idiopathic pulmonary fibrosis, Lung disease | Phase 2a Initiation | |
GRI-0803 Details Autoimmune disease, Systemic lupus erythematosus | IND Submission |